Investigational inhaled therapies for non-CF bronchiectasis
- PMID: 29338445
- DOI: 10.1080/13543784.2018.1427728
Investigational inhaled therapies for non-CF bronchiectasis
Abstract
Introduction: Bronchiectasis not related to cystic fibrosis (non-CF bronchiectasis) are associated with a high unmet therapeutic need due to the lack of specifically authorized medications, especially via the inhalation route. In non-CF bronchiectasis chronic infection with Pseudomonas aeruginosa is common and favored by the persistent local inflammation and viscid sputum production. Therefore inhaled antibiotics, mucolytics or anti-inflammatory agents could represent appropriate therapeutic interventions in this setting.
Areas covered: This review herein discusses the inhaled therapies currently under investigation for non-CF bronchiectasis and their potential therapeutic positioning in exacerbation versus stable state.
Expert opinion: Inhaled antipseudomonal antibiotics are of promising efficacy, but further efforts should also be made to detect bactericidal approaches against Burkholderia cepacia complex, and to interfere chronic inflammation topically.
Keywords: Antibiotics; Burkholderia cepacian; Pseudomonas aeruginosa; anti-inflammatory; bronchiectasis; cystic fibrosis.
Similar articles
-
The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.J Aerosol Med Pulm Drug Deliv. 2018 Jun;31(3):121-138. doi: 10.1089/jamp.2017.1415. Epub 2017 Oct 27. J Aerosol Med Pulm Drug Deliv. 2018. PMID: 29077527 Free PMC article. Review.
-
Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis.Clin Respir J. 2016 Nov;10(6):731-739. doi: 10.1111/crj.12278. Epub 2015 Mar 2. Clin Respir J. 2016. PMID: 25620629 Review.
-
Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.Chest. 2006 Nov;130(5):1503-10. doi: 10.1378/chest.130.5.1503. Chest. 2006. PMID: 17099030 Clinical Trial.
-
Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis.Semin Respir Crit Care Med. 2015 Apr;36(2):267-86. doi: 10.1055/s-0035-1547346. Epub 2015 Mar 31. Semin Respir Crit Care Med. 2015. PMID: 25826593 Review.
-
Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials.Expert Rev Respir Med. 2018 Sep;12(9):769-782. doi: 10.1080/17476348.2018.1503540. Epub 2018 Aug 3. Expert Rev Respir Med. 2018. PMID: 30025482 Review.
Cited by
-
Therapeutic Interventions for Pseudomonas Infections in Cystic Fibrosis Patients: A Review of Phase IV Trials.J Clin Med. 2024 Oct 30;13(21):6530. doi: 10.3390/jcm13216530. J Clin Med. 2024. PMID: 39518670 Free PMC article. Review.
-
Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review.Int J Med Sci. 2021 Jun 1;18(13):2849-2870. doi: 10.7150/ijms.59218. eCollection 2021. Int J Med Sci. 2021. PMID: 34220313 Free PMC article.
-
Desflurane alleviates LPS-induced acute lung injury by modulating let-7b-5p/HOXA9 axis.Immunol Res. 2024 Aug;72(4):683-696. doi: 10.1007/s12026-024-09474-9. Epub 2024 Apr 27. Immunol Res. 2024. PMID: 38676899
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources